GSK
1 year ago ⋅ English ⋅ 5 min read
Newsroom
DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma

For media and investors only- 59% reduction in risk of disease progression or death observed in patients with Blenrep combination versus standard of care daratumumab combination- 36.6 m... Read More
GSK
1 year ago ⋅ English ⋅ 4 min read
Newsroom
GSK delivers strong 2023 performance and upgrades growth outlooks

For media and investors onlyFull results announcement PDFDownload the FY 2023 results announcementFY 2023 results announcement (PDF, 942.2KB)Broad-based performance drives sales, profit... Read More
GSK
1 year ago ⋅ English ⋅ 4 min read
Newsroom
GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency for the prevention of RSV disease in adults aged 50-59 at increased risk

For media and investors only- Application supported by positive results of a Phase III study showing immune response and acceptable tolerability profile in this population- Adults aged... Read More
GSK
1 year ago ⋅ English ⋅ 7 min read
Newsroom
European Commission authorises GSK’s Omjjara (momelotinib)

For media and investors only- Omjjara is the first medicine in the EU specifically indicated for treating splenomegaly (enlarged spleen) or symptoms in adult myelofibrosis patients with... Read More
GSK
1 year ago ⋅ English ⋅ 6 min read
Newsroom
Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype

For media and investors only- Mepolizumab is the first targeted anti-Interleukin-5 (IL-5) biologic available in China as an add-on maintenance treatment for severe eosinophilic asthma-... Read More
GSK
1 year ago ⋅ English ⋅ 3 min read
Newsroom
GSK enters agreement to acquire Aiolos Bio

For media and investors only- Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway... Read More